Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
 free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 free
 free
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Neuroprotection in experimental stroke with targeted neurotrophins Wu DNeuroRx 2005[Jan]; 2 (1): 120-8More than 30 neurotrophins have been identified, and many of them have neuroprotective effects in brain ischemia or injury. However, all the clinical trials with several neurotrophins for the treatment of acute ischemic stroke or neurodegenerative diseases have failed so far, primarily because of their poor blood-brain barrier (BBB) permeability. This article is an overview of recent progress in the research focused on BBB targeted neurotrophins using a chimeric peptide approach, in which antitransferrin receptor antibody was used as a BBB delivery vector, and neurotrophin peptide was conjugated to the antibody via the avidin/biotin technology. Vasoactive intestinal peptide was the first model chimeric peptide to show an enhanced CNS effect after noninvasive peripheral administration. Brain-derived neurotrophic factor (BDNF) chimeric peptide was neuroprotective in rats subjected to transient forebrain ischemia, permanent focal ischemia, or transient focal ischemia. Delayed treatments with the BDNF chimeric peptide showed an effective time window of 1-2 h after ischemia. Basic FGF chimeric peptide was highly effective in the reduction of infarct volume in the rat model of permanent focal ischemia, with lowest effective dose of 1 mug per rat. Future studies in this exciting area include genetically engineered fusion proteins or humanized antibodies for BBB drug targeting with less immunogenicity and reduced working burden in the chemical conjugation, the use of antihuman insulin receptor antibody for higher BBB delivery efficiency, and combination therapies using chimeric neurotrophins plus other neuroprotectants to achieve additive or synergistic effects.|Animals[MESH]|Blood-Brain Barrier[MESH]|Brain Ischemia/drug therapy[MESH]|Brain-Derived Neurotrophic Factor/administration & dosage/therapeutic use[MESH]|Clinical Trials as Topic[MESH]|Fibroblast Growth Factor 2/administration & dosage/therapeutic use[MESH]|Humans[MESH]|Nerve Growth Factors/administration & dosage/pharmacokinetics/*therapeutic use[MESH]|Neuroprotective Agents/administration & dosage/pharmacokinetics/*therapeutic use[MESH]|Receptors, Transferrin/drug effects[MESH]|Recombinant Fusion Proteins/pharmacokinetics[MESH]|Stroke/*drug therapy[MESH]|Thrombolytic Therapy[MESH]|Vasoactive Intestinal Peptide/administration & dosage/pharmacology[MESH] |
